# OnCo record dalpiciclib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/dalpiciclib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "dalpiciclib" ;
  schema:name "Dalpiciclib"@en ;
  schema:description "Dalpiciclib is Hengrui's CDK4/6 inhibitor, the first China-developed drug of the class, approved for hormone-driven advanced breast cancer on the DAWNA trials."@en ;
  schema:url <https://onco.cc/drugs/dalpiciclib/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Dalpiciclib> ;
  schema:citation <https://www.hengrui.com/en/>, <https://doi.org/10.1038/s41591-021-01562-9>, <https://www.nmpa.gov.cn> ;
  onco:status "approved" ;
  onco:tag "china" ;
  onco:modality "Small-molecule CDK4/6 inhibitor" ;
  schema:alternateName "Airuikang" ;
  onco:approval "China 2021: HR-positive, HER2-negative advanced breast cancer with fulvestrant after endocrine therapy (DAWNA-1)", "China 2023: First-line HR-positive, HER2-negative advanced breast cancer with an aromatase inhibitor (DAWNA-2)" ;
  onco:cancers <https://onco.cc/cancers/breast-hr-positive/> ;
  onco:technologies <https://onco.cc/technologies/cdk46-inhibitor/>, <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/cdk4-6/> ;
  onco:companies <https://onco.cc/companies/hengrui/> ;
  onco:pathways <https://onco.cc/pathways/p53-cell-cycle/> ;
  onco:trials <https://onco.cc/trials/dawna-1/>, <https://onco.cc/trials/nct04842617/>, <https://onco.cc/trials/nct06167694/> .